Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH-oligomannose-3 complex.
BACKGROUND
Escherichia coli strains adhere to the normally sterile human uroepithelium using type 1 pili, that are long, hairy surface organelles exposing a mannose-binding FimH adhesin at the tip. A small percentage of adhered bacteria can successfully invade bladder cells, presumably via pathways mediated by the high-mannosylated uroplakin-Ia and alpha3beta1 integrins found throughout the uroepithelium. Invaded bacteria replicate and mature into dense, biofilm-like inclusions in preparation of fluxing and of infection of neighbouring cells, being the major cause of the troublesome recurrent urinary tract infections.


RESULTS
We demonstrate that alpha-D-mannose based inhibitors of FimH not only block bacterial adhesion on uroepithelial cells but also antagonize invasion and biofilm formation. Heptyl alpha-D-mannose prevents binding of type 1-piliated E. coli to the human bladder cell line 5637 and reduces both adhesion and invasion of the UTI89 cystitis isolate instilled in mouse bladder via catheterization. Heptyl alpha-D-mannose also specifically inhibited biofilm formation at micromolar concentrations. The structural basis of the great inhibitory potential of alkyl and aryl alpha-D-mannosides was elucidated in the crystal structure of the FimH receptor-binding domain in complex with oligomannose-3. FimH interacts with Man alpha1,3Man beta1,4GlcNAc beta1,4GlcNAc in an extended binding site. The interactions along the alpha1,3 glycosidic bond and the first beta1,4 linkage to the chitobiose unit are conserved with those of FimH with butyl alpha-D-mannose. The strong stacking of the central mannose with the aromatic ring of Tyr48 is congruent with the high affinity found for synthetic inhibitors in which this mannose is substituted for by an aromatic group.


CONCLUSIONS
The potential of ligand-based design of antagonists of urinary tract infections is ruled by the structural mimicry of natural epitopes and extends into blocking of bacterial invasion, intracellular growth and capacity to fluxing and of recurrence of the infection.
Wellens
Adinda
A
Department of Molecular and Cellular Interactions, VIB [corrected] Brussels, Belgium.
Garofalo
Corinne
C
Nguyen
Hien
H
Van Gerven
Nani
N
Slättegård
Rikard
R
Hernalsteens
Jean-Pierre
JP
Wyns
Lode
L
Oscarson
Stefan
S
De Greve
Henri
H
Hultgren
Scott
S
Bouckaert
Julie
J
D018830:Adhesins, Escherichia coli / Q000737:chemistry / Q000378:metabolism*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001216:Asparagine / Q000378:metabolism; D001422:Bacterial Adhesion / Q000187:drug effects; D018441:Biofilms / Q000187:drug effects; D002460:Cell Line; D018360:Crystallography, X-Ray; D003556:Cystitis / Q000382:microbiology; D004187:Disaccharides / Q000378:metabolism; D004195:Disease Models, Animal; D004926:Escherichia coli / Q000737:chemistry* / Q000187:drug effects / Q000502:physiology; D036781:Fimbriae Proteins / Q000737:chemistry* / Q000378:metabolism; D010861:Fimbriae, Bacterial / Q000187:drug effects; D006031:Glycosylation / Q000187:drug effects; D006801:Humans; D042541:Intracellular Space / Q000187:drug effects / Q000378:metabolism; D008362:Mannosides / Q000378:metabolism; D051379:Mice; D009844:Oligosaccharides / Q000737:chemistry*; D017434:Protein Structure, Tertiary; D011956:Receptors, Cell Surface / Q000378:metabolism; D013379:Substrate Specificity / Q000187:drug effects; D014552:Urinary Tract Infections / Q000188:drug therapy*
D018830:Adhesins, Escherichia coli; D000900:Anti-Bacterial Agents; D004187:Disaccharides; D008362:Mannosides; D009844:Oligosaccharides; D011956:Receptors, Cell Surface; C058769:fimH protein, E coli; D036781:Fimbriae Proteins; C032438:chitobiose; D001216:Asparagine